FindTrial
Sign In

A study to determine the effectiveness of newly diagnosed multiple myeloma patients after treatment using daratumumab-botetazomib-thalidomide-dexamethasone combination therapy or bortezomib-renalidomide-dexamethasone combination therapy

Prospective observational study to identify efficacy of induction treatments consist of daratumumab-bortezomib-thalidomide-dexamethasone or bortezomib-lenalidomide-dexamethasone in transplant-eligible newly diagnosed multiple myeloma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0010420
Enrollment
200
Registered
2025-04-16
Start date
2025-04-21
Completion date
Unknown
Last updated
2025-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

The Catholic University of Korea, Seoul St. Mary's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Patients over 19 years old 2)Patients diagnosed with multiple myeloma in need of treatment 3)Patients planning velcade, lenalidomide, dexamethasone combination therapy and subsequent autologous hematopoietic stem cell transplantation according to intent to treat analysis's plan

Exclusion criteria

Exclusion criteria: 1) Neutrophil count <1,000/mm3 at the time of study registration 2) Platelet count <80,000/mm3 at the time of study registration 3) a pregnant woman or a lactating woman

Design outcomes

Primary

MeasureTime frame
Minimal Residual Disease—

Secondary

MeasureTime frame
Progression - free survival—

Countries

Korea, Republic of

Contacts

Public ContactSoYoung Lee

The Catholic University of Korea, Seoul St. Mary's Hospital

soyounglee7533@gmail.com+82-2-2258-1950

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026